OrphoMed Announces Formation of Scientific Advisory Board

– Board Includes Six Members Recognized as Industry Experts in Gastrointestinal Disorders –

December 18, 2018

SAN FRANCISCO, CA– OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, announced today the formation of a Scientific Advisory Board (SAB) comprised of six experts in gastrointestinal disorders and drug discovery and development, who are faculty at world-leading medical institutions.

The SAB will work closely with the OrphoMed leadership team as the Company continues to advance the clinical development of its lead drug candidate ORP-101, a potential best-in-class therapeutic for the treatment of diarrhea predominant irritable bowel syndrome (IBS-D).

“We are excited and privileged to have the opportunity to work with this group of experts on the development of ORP-101 as well as on our broader pipeline of dimer therapeutics,” said Gary Phillips, M.D., OrphoMed’s President and Chief Executive Officer. “These thought-leaders bring tremendous understanding of gastrointestinal disorders, as well as extensive experience in drug development from discovery through to late-stage clinical trials. We look forward to their contributions as OrphoMed enters a new stage in advancing ORP-101 into Phase 2 clinical development.”

The SAB will be comprised of the following members:


Anthony J. Lembo, M.D., Harvard Medical School and Beth Israel Deaconess Medical Center
Anthony J. Lembo, M.D. is Director of Motility Services at Beth Israel Deaconess Medical Center and an Associate Professor of Medicine at Harvard Medical School. His research interests include functional bowel disorders such as IBS, chronic constipation, and dyspepsia. His research interests also include studying the role of placebo in functional bowel disorders. He received his M.D. from Tufts University School of Medicine. For more information on Dr. Lembo, please visit https://findadoc.bidmc.org/details/890/anthony-lembo-gastroenterology-boston-wellesley.

Lin Chang, M.D., David Geffen School of Medicine, University of California, Los Angeles (UCLA)
Lin Chang, M.D. is the Vice-Chief at the Vatche and Tamar Manounkian Division of Digestive Diseases, Program Director of the UCLA GI Fellowship Program, and Co-Director of the G. Oppenheimer Center for Neurobiology of Stress and Resilience (CNSR). She is also a Professor of Medicine at the David Geffen School of Medicine at UCLA. Her clinical expertise is in functional gastrointestinal disorders, and her research is focused on the pathophysiology of IBS related to stress, sex differences, genetic and epigenetic factors, neuroendocrine alterations, and gut microbiome and the treatment of IBS. Dr. Chang received her M.D. from UCLA School of Medicine. For more information on Dr. Chang, please visit https://www.uclahealth.org/lin-chang.

William Chey, M.D., University of Michigan School of Public Health
William Chey, M.D. is a Professor of Internal Medical and Nutritional Sciences at Michigan Medicine. His research includes the pathophysiology and management of functional bowel disorders, diagnostic tests and therapy for Helicobacter pylori, and the emerging role of web-based and app-based patient-provider tools in medicine. He received his M.D. from Emory University School of Medicine. For more information on Dr. Chey, please visit https://sph.umich.edu/faculty-profiles/chey-william.html.

David J. Greenblatt, M.D., Tufts University School of Medicine
David J. Greenblatt, M.D. holds the Louis Lasagna, M. D., Endowed Professorship at Tufts University School of Medicine, and is a senior faculty member in the Graduate Program in Pharmacology & Experimental Therapeutics at the Sackler School of Graduate Biomedical Sciences at Tufts University. He also holds appointments as Professor of Psychiatry, Medicine, and Anesthesia, Tufts University School of Medicine. His research work focuses on the following areas: molecular and clinical pharmacokinetics/pharmacodynamics; genetic and environmental factors regulating drug metabolism by Cytochromes P450 and glucuronosyl transferases, and energy-dependent transport by P-glycoprotein and other transporters; mechanisms, consequences, and in vitro prediction of metabolic drug-drug interactions attributable to enzyme inhibition and induction; effect of age, gender, body habitus, and dietary composition on drug disposition and response; drug interactions involving nutrients and natural substances; molecular and clinical determinants of ligand binding and pharmacodynamic response to centrally-acting drugs. He received his M.D. from Harvard Medical School. For more information on Dr. Greenblatt, please visit https://sackler.tufts.edu/facultyResearch/faculty/greenblatt-david.

Pankaj Jay Pasricha, M.B.B.S., M.D., The Johns Hopkins Hospital
Pankaj Jay Pasricha, M.B.B.S., M.D. practices at The Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center. He is also Professor of Innovation Management at the Johns Hopkins Carey School of Business and is leading the establishment of the Johns Hopkins Center for Neurogastroenterology. His research focuses on clinical disorders associated with gastroenterological motility, the biology of the enteric nervous system and visceral pain, neural stem cells and technology development associated with endoscopic research and advancements. He received his M.D. from All-India Institute of Medical Sciences. For more information on Dr. Pasricha, please visit https://www.hopkinsmedicine.org/profiles/results/directory/profile/8897935/pankaj-pasricha.

Ron Schey, M.D., University of Florida College of Medicine
Ron Schey, M.D. is a Professor of Medicine, and Medical Director of the Neurogastroenterology and Esophageal Program at the Department of Medicine, Division of Gastroenterology, University of Florida College of Medicine – Jacksonville. His research focuses mainly on gastrointestinal motility disorders. He received his M.D. from the Sackler School of Medicine at Tel-Aviv University. For more information on Dr. Schey, please visit https://hscj.ufl.edu/directory/bio/3264/ron-schey/.

About OrphoMed, Inc.

OrphoMed is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class dimer therapeutics. Leveraging its proprietary dimer platform technology engineered by Founder Nikhilesh Singh, Ph.D., OrphoMed is advancing ORP-101, a potential best-in-class buprenorphine dimer in clinical development for the treatment of IBS-D, and its pipeline of additional dimer conjugates. In May 2017, OrphoMed completed a $39 million Series A financing with New Enterprise Associates, Takeda Ventures, Pappas Capital and Relativity Healthcare. For more information please visit www.orphomed.com.


This press release contains “forward-looking statements,” which reflect our current views and expectations with respect to future outcomes or events. When used in this press release, the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Because these statements are based on current estimates and assumptions, they are inherently subject to risks that could cause the actual outcomes to differ materially from what we currently expect. These forward-looking statements are subject to numerous risks and uncertainties, including, among others, the facts that we are substantially dependent on our ability to successfully develop and commercialize our products; the commercial adoption of our products and any other product candidates we develop will depend on the degree of their market acceptance; we have only limited assets and will need to raise additional capital before we can expect to generate revenue or become profitable; and we have never generated any revenue and may never be profitable. Forward-looking statements in this presentation apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.

Gregory L. Beyer
(415) 569-4417